NCT05554393 – A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy
This Phase II trial, part of the National Cancer Institute’s myeloMATCH initiative, compares three treatment approaches for newly diagnosed younger patients with intermediate risk acute myeloid leukemia (AML), guided by measurable residual disease (MRD) testing. Patients are assigned to receive cytarabine plus daunorubicin, cytarabine plus daunorubicin plus venetoclax, or venetoclax plus azacitidine. Cytarabine and daunorubicin work by interfering with DNA replication and repair to slow or stop cancer cell growth. After completing treatment, patients are followed for 5 years, with clinic visits 28 days after treatment ends, then every 3 months in year one, every 6 months in year two, and annually for years three through five. Patients may also be offered enrollment in another myeloMATCH trial after finishing this study.